Investing.com -- Vericel (NASDAQ:VCEL) Corporation shares fell 11% after market close as the company reported preliminary total revenue for the fourth quarter that did not meet the average analyst estimate.
The biopharmaceutical company's preliminary total revenue fell between $75.2 million and $75.7 million, falling short of the estimated $77.9 million, according to the Bloomberg Consensus.
The company's MACI (matrix-induced autologous chondrocyte implant) net revenue was within the range of $68.2 million to $68.7 million, slightly surpassing the estimate of $68.1 million.
However, the preliminary Epicel (cultured epidermal autografts) net revenue was about $6 million, which was lower than the estimated $8.38 million. The preliminary NexoBrid revenue was about $1 million, under the estimated $1.47 million.
For the year ahead, Vericel predicts an adjusted Ebitda margin of 25% to 26%. The company also expects a gross margin in the range of 73% to 74%, which is slightly higher than the estimated 72.4%.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Should you invest $2,000 in VCEL right now?
With VCEL making headlines, savvy investors are asking: Is it truly valued fairly? In a market full of overpriced darlings, identifying true value can be challenging. InvestingPro's advanced AI algorithms have analyzed VCEL alongside thousands of other stocks to uncover hidden gems. These undervalued stocks, potentially including VCEL, could offer substantial returns as the market corrects. In 2024 alone, our AI identified several undervalued stocks that later surged by 30 or more. Is VCEL poised for similar growth? Don't miss the opportunity to find out.
Reveal Undervalued Stocks Now